Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
- 29 June 2007
- Vol. 25 (34) , 6334-6340
- https://doi.org/10.1016/j.vaccine.2007.06.017
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccinesVaccine, 2005
- SARS Vaccine DevelopmentEmerging Infectious Diseases, 2005
- Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humansSeminars in Immunology, 2005
- SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirusVaccine, 2005
- Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly HumansJournal of Virology, 2005
- Protollin™: a novel adjuvant for intranasal vaccinesVaccine, 2004
- Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in miceVaccine, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- The Genome Sequence of the SARS-Associated CoronavirusScience, 2003
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003